Liver stiffness decrease after effective antiviral therapy in patients with chronic hepatitis C: Longitudinal study using FibroScan

Wang, Jing‐Houng; Changchien, Chi‐Sin; Hung, Chao‐Hung; Tung, Wei-Chih; Kee, Kwong‐Ming; Chen, Chien‐Hung; Hu, Tsung–Hui; Lee, Chuan–Mo; Lu, Sheng–Nan

doi:10.1111/j.1440-1746.2009.06194.x

Cited by 75 publications

(76 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This observation has already been made in earlier studies [35][36][37][38][39]. In our cohort, the range of changes in kPa was −4.2 to 41.8 kPa between baseline and FU24, 2.3 kPa to 29 kPa between baseline and FU96, and −2.6 to 18.7 between EOT and FU96.…”

Section: Discussionsupporting

confidence: 70%

Effect of HCV Core Antigen and RNA Clearance during Therapy with Direct Acting Antivirals on Hepatic Stiffness Measured with Shear Wave Elastography in Patients with Chronic Viral Hepatitis C

Łucejko

Flisiak

2018

Applied Sciences

View full text Add to dashboard Cite

Abstract:To assess a combination of novel measures of therapeutic success in the treatment of chronic hepatitis C (CHC) infection, we evaluated liver stiffness (LS) with shear wave elastography and hepatitis C virus core antigen (HCVcAg) concentrations. We followed 34 patients during and after treatment with direct acting antivirals. All patients achieved a sustained virologic and serologic response and a significant increase of albumin levels. Decreases of alanine aminotransferase (ALT) activity and alpha-fetoprotein (AFP) level were observed during the treatment and follow-up period. A significant decrease in LS was observed between baseline, end of treatment (EOT), and at 24-and 96-week post-treatment follow-up. LS decline between EOT and 96-week follow-up (FU96) was observed in 79% of patients. Significant LS changes were seen in patients with advanced fibrosis, particularly in cirrhotics and in patients with ALT exceeding 100 IU/mL. There was a positive correlation between ALT activity and LS changes at the baseline versus FU96. A negative correlation was demonstrated between individual HCVcAg baseline concentrations and reduction of LS at the baseline versus FU96. In conclusion, we observed that LS significantly declined during and after antiviral treatment. It was accompanied by improvement in some liver function measures, and disappearance of both HCVcAg and HCV ribonucleic acid (HCV RNA).

show abstract

Section: Discussionsupporting

confidence: 70%

Effect of HCV Core Antigen and RNA Clearance during Therapy with Direct Acting Antivirals on Hepatic Stiffness Measured with Shear Wave Elastography in Patients with Chronic Viral Hepatitis C

Łucejko

Flisiak

2018

Applied Sciences

View full text Add to dashboard Cite

show abstract

“…Fibroscan has previously been used to evaluate the degree of liver fibrosis in patients with hepatitis B (11), hepatitis C (12,13) cirrhosis (14), alcoholic liver disease (15,16) and autoimmune liver diseases (17). It is also used in antiviral therapy efficacy evaluation (18,19).…”

Section: Introductionmentioning

confidence: 99%

Influencing factors of transient elastography in detecting liver stiffness

Shi

Yin

Yang

et al. 2016

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. Liver stiffness, which correlates well with liver fibrosis stage, can be measured noninvasively by transient elastography, also known as Fibroscan. The present study aimed to determine the independent factors influencing Fibroscan detection by multiple regression analysis. A total of 181 patients who required liver biopsy were enrolled. Liver stiffness measurement (LSM) was detected by Fibroscan on the day of liver biopsy, while clinical information and routine biochemical examination results were also collected. Correlation was analyzed by Spearman's correlation, and multiple regression analysis was performed to analyze the independent influencing factors. The results demonstrated that platelet (PLT) levels, serum albumin (ALB), prothrombin activity (PTA) and body mass index (BMI) were independent predictors of liver stiffness. The contribution of these four predictors to the regression equation was in the following descending order: PLT (negative correlation) > ALB (negative correlation) > PTA (negative correlation) > BMI (positive correlation). In conclusion, the parameters of PLT, ALB, PTA and BMI are independent predicting factors affecting Fibroscan detection. Therefore, the diagnosis and evaluation of liver fibrosis should comprehensively consider the results of Fibroscan, and clinical and laboratory examinations.

show abstract

“…Successful eradication of HCV could improve the prognosis of HCV-induced liver disease and reduce the associated mortality (23,27). Hence, in areas where HCV is endemic, it is important to identify the individuals with an ongoing active infection to administer further anti-HCV treatment.…”

Section: Discussionmentioning

confidence: 99%

“…Successful eradication of HCV has been shown to improve the prognosis of HCV-induced liver disease and reduce the associated mortality (23,27). Hence, to adequately screen individuals with an active infection is a crucial issue in areas where HCV is endemic (24).…”

mentioning

confidence: 99%

Is Hepatitis C Virus Core Antigen an Adequate Marker for Community Screening?

et al. 2012

Self Cite

View full text Add to dashboard Cite

A new hepatitis C virus (HCV) core antigen (HCV Ag) assay was thought to have a good correlation with HCV RNA. The aim was to elucidate the usefulness of this HCV Ag assay in community screening. In a township where HCV is endemic, 405 residents aged 58 years or older responded to a follow-up community screening. All subjects were tested for anti-HCV (AxSYM, version 3.0; Abbott Diagnostics) and HCV Ag (Architect HCV Ag test; Abbott Diagnostics). For subjects with anti-HCV signal-to-cutoff ratios (S/CO) > 10 and/or HCV Ag > 3 fmol/liter, HCV RNA data (Taqman HCV RNA; Roche Diagnostics) were further checked. A total of 115 (28.4%) subjects had their serum HCV RNA levels measured, and 93 were HCV RNA positive. The other 290 subjects were supposed to be HCV RNA negative. HCV Ag was significantly correlated with HCV RNA according to the following equation: (log HCV RNA) ‫؍‬ 2.08 ؉ 1.03 (log HCV Ag) (R 2 ‫؍‬ 0.94; P < 0.001). As determined using a combination of the values for anti-HCV (S/CO > 40) and HCV Ag (>3 fmol/liter) as a cutoff to predict viremia, the sensitivity, specificity, accuracy, positive predictive value, and negative predictive value were 96.8%, 100%, 99.3%, 100%, and 99%, respectively. In conclusion, for a community study, HCV Ag showed good correlation with HCV RNA. In addition, anti-HCV or HCV Ag can predict HCV viremia well, while a combination of anti-HCV (>40 S/CO) and HCV Ag (>3 fmol/liter) can provide the best result validity.C hronic hepatitis C virus (HCV) infection is a common etiology of liver cirrhosis and hepatocellular carcinoma, with an estimated 170 million chronic carriers worldwide (9, 22). Successful eradication of HCV has been shown to improve the prognosis of HCV-induced liver disease and reduce the associated mortality (23,27). Hence, to adequately screen individuals with an active infection is a crucial issue in areas where HCV is endemic (24).In clinical practice, diagnosis of HCV infection in hospitals is usually based on the detection of anti-HCV antibodies in the serum. Several anti-HCV assays have been used as the common serological marker for HCV infection for more than 20 years. However, most assays cannot distinguish infected individuals with an ongoing active infection from those who have recovered from acute infection. Unlike anti-HCV antibodies, serum HCV RNA is a reliable marker for the diagnosis of an ongoing HCV infection and is usually used for monitoring anti-HCV treatment. But its high cost, and the requirement for considerable technical skill and related equipment, limit its routine use in community screening (16).The HCV core antigen (HCV Ag) possibly exists in both complete HCV virions and RNA-free core protein structures and has been detected in the serum of infected individuals (8,13,20). Several HCV Ag assays developed in the last decade have been shown to have good correlation with HCV RNA assays (3,21,25,28). Hence, these assays were used as an alternative to HCV RNA for the diagnosis of active HCV infection as well as for the monitoring of the response...

show abstract

Liver stiffness decrease after effective antiviral therapy in patients with chronic hepatitis C: Longitudinal study using FibroScan

Abstract: LS decreases in sustained responders following IFN-based therapy in patients with chronic HCV. Advanced fibrosis, higher BMI, longer time for remission and lower initial LS value are predictive factors for a slow improvement of LS in sustained responders.

Cited by 75 publications

References 36 publications

Effect of HCV Core Antigen and RNA Clearance during Therapy with Direct Acting Antivirals on Hepatic Stiffness Measured with Shear Wave Elastography in Patients with Chronic Viral Hepatitis C

Effect of HCV Core Antigen and RNA Clearance during Therapy with Direct Acting Antivirals on Hepatic Stiffness Measured with Shear Wave Elastography in Patients with Chronic Viral Hepatitis C

Influencing factors of transient elastography in detecting liver stiffness

Is Hepatitis C Virus Core Antigen an Adequate Marker for Community Screening?

Contact Info

Product

Resources

About